BACKGROUND & AIMS: Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies in patients' serum. The major autoantigen, recognized by antibodies from > 95% of patients with PBC, has been identified as the E2 component (E2p) of the pyruvate dehydrogenase multienzyme complex. Immunodominant sites on E2p have been localized to the inner of the two lipoyl domains, where the essential cofactor lipoic acid is attached covalently. The aim of this study was to determine the three-dimensional structure of the inner lipoyl domain of human E2p. METHODS: The domain was expressed in Escherichia coli; after purification, its structure was analyzed using nuclear magnetic resonance spectroscopy. RESULTS: The structure of the lipoyl domain from human E2p was determined, and the implications of the structure for autoimmune recognition were assessed. CONCLUSIONS: Knowledge of the structure further defines the major epitope and may help in the design of antigen-specific immunotherapy for treatment of PBC.
BACKGROUND & AIMS:Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies in patients' serum. The major autoantigen, recognized by antibodies from > 95% of patients with PBC, has been identified as the E2 component (E2p) of the pyruvate dehydrogenase multienzyme complex. Immunodominant sites on E2p have been localized to the inner of the two lipoyl domains, where the essential cofactor lipoic acid is attached covalently. The aim of this study was to determine the three-dimensional structure of the inner lipoyl domain of humanE2p. METHODS: The domain was expressed in Escherichia coli; after purification, its structure was analyzed using nuclear magnetic resonance spectroscopy. RESULTS: The structure of the lipoyl domain from humanE2p was determined, and the implications of the structure for autoimmune recognition were assessed. CONCLUSIONS: Knowledge of the structure further defines the major epitope and may help in the design of antigen-specific immunotherapy for treatment of PBC.
Authors: Zongwen Shuai; Jinjun Wang; Madhu Badamagunta; Jinjung Choi; Guoxiang Yang; Weici Zhang; Thomas P Kenny; Kathryn Guggenheim; Mark J Kurth; Aftab A Ansari; John Voss; Ross L Coppel; Pietro Invernizzi; Patrick S C Leung; M Eric Gershwin Journal: Hepatology Date: 2017-03-31 Impact factor: 17.425
Authors: Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava Journal: Clin Rev Allergy Immunol Date: 2014-08 Impact factor: 8.667
Authors: Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin Journal: Expert Rev Mol Diagn Date: 2016-03-30 Impact factor: 5.225
Authors: S Vijayakrishnan; S M Kelly; R J C Gilbert; P Callow; D Bhella; T Forsyth; J G Lindsay; O Byron Journal: J Mol Biol Date: 2010-03-31 Impact factor: 5.469
Authors: Patrick S C Leung; Jinjun Wang; Phornnop Naiyanetr; Thomas P Kenny; Kit S Lam; Mark J Kurth; M Eric Gershwin Journal: J Autoimmun Date: 2013-01-24 Impact factor: 7.094